exenatide vs tirzepatide (a GLP-1 receptor agonist) rapidly lowered intracranial pressure in active IIH, with a sustained signal at 12 weeks and no meaningful weight change. The authors suggest an ICP-lowering Cardiovascular outcomes of semaglutide and

However, this result relied entirely on unadjusted data, was driven largely by a single large cohort, and lacked detail on specific malformation subtypes, limiting how much can be concluded from it

doi: 10.1016/j.cmet.2012.06.015 31 AlhadeffALBairdJ-PSwickJCHayesMRGrillHJ

CONTRAVE should be used with a reduced-calorie diet and increased physical activity

Data from January 2014 when the FDA first approved these medications, to August 2022 were included in their analyses with comparisons made between people with either alcohol or opioid use disorder who were prescribed these medications vs

For the anti-obesity medication (AOM) cohort, patients who had one or more pharmacy claims for Zepbound or Wegovy between 1 November 2023, and 31 December 2023, were identified (identification period)

Our medical weight loss program includes the following: It seems like every other person we encounter in public is overweight